Literature DB >> 9845827

Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence.

C Y Lin1, W P Chen, L Y Yang, A Chen, T P Huang.   

Abstract

The efficiency of continuous ambulatory peritoneal dialysis depends on the permeability of the peritoneal membrane. Peritoneal fibrosis (PF) causes loss of the dialytic function. Several studies have indicated that PF is closely related to the proliferation of peritoneal fibroblasts and the deposition of extracellular matrix. Transforming growth factor-beta 1 (TGF-beta1) plays a major role in stimulating extracellular matrix deposition. Frequent peritonitis occurrence may cause persistent TGF-beta1 mRNA expression. In an attempt to search for a factor related to PF, we designed a longitudinal study to measure TGF-beta1 levels in dialysate and TGF-beta1 mRNA expression in peritoneal mononuclear cells from peritoneal dialysate before onset, once a week during peritonitis, and after peritonitis in high and low peritonitis occurrence (HPO and LPO) patients. Fifteen patients with a LPO rate and 5 patients with a HPO rate were followed up longitudinally. Meanwhile, TGF-beta1 levels and TGF-beta1 mRNA expression were augmented in peritoneal dialysate effluents before, during, and after the episodes of peritonitis. The peritoneal permeability was evaluated by the peritoneal equilibration test. The results revealed that in the LPO group, TGF-beta1 and TGF-beta1 mRNA were detectable at early stages of peritonitis, but the levels decreased rapidly and were undetectable 2 weeks after peritonitis. On the other hand, in the HPO group, TGF-beta1 and TGF-beta1 mRNA persisted for a long time. We could detect TGF-beta1 and TGF-beta1 mRNA in dialysate effluents and peritoneal mononuclear cells even 2, 3, and 4 weeks after episodes of peritonitis. When compared with that of first or second episode of peritonitis, the peritoneal function evaluated with the peritoneal equilibration test was found to obviously deteriorate during the third episode of peritonitis. These findings were confirmed by an in situ hybridization technique to evaluate the relationship between TGF-beta1 mRNA expression and PF from biopsied peritoneal specimens. These findings suggest that the high TGF-beta1 levels in the dialysate are related to an increased expression of TGF-beta1 in the peritoneum. Thus, the persistent TGF-beta1 expression in the peritoneum may serve as a useful parameter in predicting PF in continuous ambulatory peritoneal dialysis patients with frequent peritonitis occurrence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845827     DOI: 10.1159/000013397

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  9 in total

1.  Comparison of sirolimus and colchicine treatment on the development of peritoneal fibrozis in rats having peritoneal dialysis.

Authors:  Tamer Sağıroğlu; Mustafa Burak Sayhan; Mehmet A Yağcı; Tülin Yalta; Gönül Sağıroğlu; Elif Çopuroğlu; Serhat Oğuz
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

2.  MicroRNA-29b inhibits peritoneal fibrosis in a mouse model of peritoneal dialysis.

Authors:  Jian-Wen Yu; Wen-Juan Duan; Xiao-Ru Huang; Xiao-Ming Meng; Xue-Qing Yu; Hui-Yao Lan
Journal:  Lab Invest       Date:  2014-07-21       Impact factor: 5.662

3.  Role of transforming growth factor beta-1 in peritonitis-induced adhesions.

Authors:  A M Ghellai; A F Stucchi; N Chegini; C Ma; C D Andry; J M Kaseta; J W Burns; K C Skinner; J M Becker
Journal:  J Gastrointest Surg       Date:  2000 May-Jun       Impact factor: 3.452

Review 4.  Proteomics and Extracellular Vesicles as Novel Biomarker Sources in Peritoneal Dialysis in Children.

Authors:  Chiara Trincianti; Vincenzo Meleca; Edoardo La Porta; Maurizio Bruschi; Giovanni Candiano; Andrea Garbarino; Xhuliana Kajana; Alberto Preda; Francesca Lugani; Gian Marco Ghiggeri; Andrea Angeletti; Pasquale Esposito; Enrico Verrina
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

5.  Treatment of established peritoneal fibrosis by gene transfer of Smad7 in a rat model of peritoneal dialysis.

Authors:  Yanyan Sun; Fengxin Zhu; Xueqing Yu; Jing Nie; Fengxian Huang; Xiaoyan Li; Ning Luo; Hui Yao Lan; Yongtao Wang
Journal:  Am J Nephrol       Date:  2009-02-18       Impact factor: 3.754

6.  Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum.

Authors:  Peter J Margetts; Martin Kolb; Lisa Yu; Catherine M Hoff; Clifford J Holmes; Daniel C Anthony; Jack Gauldie
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 7.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

Review 8.  Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease.

Authors:  Zia Moinuddin; Angela Summers; David Van Dellen; Titus Augustine; Sarah E Herrick
Journal:  Front Physiol       Date:  2015-01-05       Impact factor: 4.566

9.  Relationship between initial peritoneal dialysis modality and risk of peritonitis.

Authors:  Maiko Kokubu; Masaru Matsui; Takayuki Uemura; Katsuhiko Morimoto; Masahiro Eriguchi; Kenichi Samejima; Yasuhiro Akai; Kazuhiko Tsuruya
Journal:  Sci Rep       Date:  2020-10-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.